Literature DB >> 24594138

Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.

Tracy A Manuck1, W Scott Watkins2, Barry Moore2, M Sean Esplin1, Michael W Varner1, G Marc Jackson1, Mark Yandell2, Lynn Jorde2.   

Abstract

OBJECTIVE: We hypothesized that genetic variation affects responsiveness to 17-alpha hydroxyprogesterone caproate (17P) for recurrent preterm birth prevention. STUDY
DESIGN: Women of European ancestry with ≥1 spontaneous singleton preterm birth at <34 weeks' gestation who received 17P were recruited prospectively and classified as a 17P responder or nonresponder by the difference in delivery gestational age between 17P-treated and -untreated pregnancies. Samples underwent whole exome sequencing. Coding variants were compared between responders and nonresponders with the use of the Variant Annotation, Analysis, and Search Tool (VAAST), which is a probabilistic search tool for the identification of disease-causing variants, and were compared with a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway candidate gene list. Genes with the highest VAAST scores were then classified by the online Protein ANalysis THrough Evolutionary Relationships (PANTHER) system into known gene ontology molecular functions and biologic processes. Gene distributions within these classifications were compared with an online reference population to identify over- and under- represented gene sets.
RESULTS: Fifty women (9 nonresponders) were included. Responders delivered 9.2 weeks longer with 17P vs 1.3 weeks' gestation for nonresponders (P < .001). A genome-wide search for genetic differences implicated the NOS1 gene to be the most likely associated gene from among genes on the KEGG candidate gene list (P < .00095). PANTHER analysis revealed several over-represented gene ontology categories that included cell adhesion, cell communication, signal transduction, nitric oxide signal transduction, and receptor activity (all with significant Bonferroni-corrected probability values).
CONCLUSION: We identified sets of over-represented genes in key processes among responders to 17P, which is the first step in the application of pharmacogenomics to preterm birth prevention. Published by Mosby, Inc.

Entities:  

Keywords:  pharmacogenomics; progesterone; spontaneous preterm birth

Mesh:

Substances:

Year:  2014        PMID: 24594138      PMCID: PMC4266558          DOI: 10.1016/j.ajog.2014.01.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  36 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

Review 2.  Epidemiology of preterm birth and its clinical subtypes.

Authors:  Cande V Ananth; Anthony M Vintzileos
Journal:  J Matern Fetal Neonatal Med       Date:  2006-12

3.  A functional SNP in the promoter of the SERPINH1 gene increases risk of preterm premature rupture of membranes in African Americans.

Authors:  Hongyan Wang; Samuel Parry; George Macones; Mary D Sammel; Helena Kuivaniemi; Gerard Tromp; George Argyropoulos; Indrani Halder; Mark D Shriver; Roberto Romero; Jerome F Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

4.  Nitric oxide synthase activity in the pregnant uterus decreases at parturition.

Authors:  E S Natuzzi; P C Ursell; M Harrison; C Buscher; R K Riemer
Journal:  Biochem Biophys Res Commun       Date:  1993-07-15       Impact factor: 3.575

5.  Preterm birth in rats produced by the synergistic action of a nitric oxide inhibitor (NG-nitro-L-arginine methyl ester) and an antiprogestin (onapristone).

Authors:  C Yallampalli; I Buhimschi; K Chwalisz; R E Garfield; Y L Dong
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

6.  The risk of preterm birth across generations.

Authors:  T F Porter; A M Fraser; C Y Hunter; R H Ward; M W Varner
Journal:  Obstet Gynecol       Date:  1997-07       Impact factor: 7.661

7.  Familial patterns in birth characteristics: impact on individual and population risks.

Authors:  A Winkvist; I Mogren; U Högberg
Journal:  Int J Epidemiol       Date:  1998-04       Impact factor: 7.196

8.  Relaxant effects of nitric oxide and cyclic GMP on pregnant rat uterine longitudinal smooth muscle.

Authors:  H Izumi; R E Garfield
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1995-06       Impact factor: 2.435

9.  The Randomized Nitric Oxide Tocolysis Trial (RNOTT) for the treatment of preterm labor.

Authors:  A Bisits; G Madsen; M Knox; A Gill; R Smith; G Yeo; K Kwek; M Daniel; T N Leung; K Cheung; T Chung; I Jones; J Toohill; D Tudehope; W Giles
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

Review 10.  Genetic variation associated with preterm birth: a HuGE review.

Authors:  Krista S Crider; Nedra Whitehead; Rebecca M Buus
Journal:  Genet Med       Date:  2005 Nov-Dec       Impact factor: 8.822

View more
  13 in total

1.  Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.

Authors:  Tracy A Manuck; Gregory J Stoddard; Rebecca C Fry; M Sean Esplin; Michael W Varner
Journal:  Am J Obstet Gynecol       Date:  2016-07-11       Impact factor: 8.661

2.  Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.

Authors:  Tracy A Manuck; M Sean Esplin; Joseph Biggio; Radek Bukowski; Samuel Parry; Heping Zhang; Hao Huang; Michael W Varner; William Andrews; George Saade; Yoel Sadovsky; Uma M Reddy; John Ilekis
Journal:  Am J Obstet Gynecol       Date:  2015-12-12       Impact factor: 8.661

3.  17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.

Authors:  David B Nelson; Donald D McIntire; Jeffrey McDonald; John Gard; Paula Turrichi; Kenneth J Leveno
Journal:  Am J Obstet Gynecol       Date:  2017-02-20       Impact factor: 8.661

4.  Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.

Authors:  Kent D Heyborne; Amanda A Allshouse
Journal:  Am J Perinatol       Date:  2016-07-27       Impact factor: 1.862

5.  Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.

Authors:  Tracy A Manuck; Lisa Smeester; Elizabeth M Martin; Martha S Tomlinson; Christina Smith; Michael W Varner; Rebecca C Fry
Journal:  Am J Perinatol       Date:  2017-12-14       Impact factor: 1.862

Review 6.  Pharmacogenomics of preterm birth prevention and treatment.

Authors:  T A Manuck
Journal:  BJOG       Date:  2015-11-06       Impact factor: 6.531

7.  Mid-pregnancy maternal blood nitric oxide-related gene and miRNA expression are associated with preterm birth.

Authors:  Tracy A Manuck; Lauren A Eaves; Julia E Rager; Rebecca C Fry
Journal:  Epigenomics       Date:  2021-04-23       Impact factor: 4.778

8.  The Effect of Progestins on Tumor Necrosis Factor α-Induced Matrix Metalloproteinase-9 Activity and Gene Expression in Human Primary Amnion and Chorion Cells In Vitro.

Authors:  Terrence K Allen; Liping Feng; Matthew Nazzal; Chad A Grotegut; Irina A Buhimschi; Amy P Murtha
Journal:  Anesth Analg       Date:  2015-05       Impact factor: 6.627

9.  Refining Pharmacologic Research to Prevent and Treat Spontaneous Preterm Birth.

Authors:  Tracy A Manuck
Journal:  Front Pharmacol       Date:  2017-03-15       Impact factor: 5.810

10.  Nitric oxide-related gene and microRNA expression in peripheral blood in pregnancy vary by self-reported race.

Authors:  Tracy A Manuck; Lauren A Eaves; Julia E Rager; Karen Sheffield-Abdullah; Rebecca C Fry
Journal:  Epigenetics       Date:  2021-07-24       Impact factor: 4.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.